A Study of LY3439539 in Participants With Alzheimer's Disease

ConditionAlzheimer Disease

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age50-85

SponsorEli Lilly and Company

About this trial

The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.

Participation in the study will last approximately 9 months with visits about once a month.

Eligibility criteria

Qualifiers

Have gradual and progressive change in memory function reported by the participant or informant for 6 months or longer consistent with a diagnosis of dementia due to Alzheimer's disease

Have a Mini Mental Score Examination score of 16 to 24, inclusive

Meet plasma pTau criteria, as defined by the sponsor

Have body mass index within the range of 17 and 32 kilograms per square meter (kg/m²) (inclusive) at screening

Disqualifiers

Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.

Have a screening MRI that shows evidence of significant abnormality.

Have history of suicidal behavior, or a lifetime history of suicide attempt or acute suicidality.

Have a history of